13 results about "Fasting glucose" patented technology

The invention provides a sugar fat disease death risk prediction method and system based on NHANES data, and the method comprises the steps: obtaining the fasting blood glucose FPG and glycosylated hemoglobin HbA1c clinical detection data of a sugar fat disease patient, and calculating an SHR value through a formula; based on the data of the NHANES database, SHR total cause bilateral critical values of total cause death rate and cardiovascular death rate, SHR cardiovascular bilateral critical values and SHR cancer unilateral critical values of cancer death rate are obtained; and comparing the SHR value with an SHR total cause double-side critical value, an SHR cardiovascular double-side critical value and an SHR cancer single-side critical value of the cancer death rate, and carrying out risk layering and evaluation. The biochemical aging acceleration index has a prediction effect on the diabetes death risk, and KDMAgeAccel significantly intermediates the death risk caused by SHR.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The invention provides application of nitraria tangutorum bobr extract in preparation of products for regulating glycolipid metabolism disorder, and relates to the technical field of plant extract application. The nitraria macrocarpa extract is a composition rich in alkaloid and flavonoid compounds, wherein the sum of the content of total alkaloid and the content of total flavonoids is not lower than 85% of the total weight of the extract. The extract is prepared through the processes of fresh fruit juicing, alcohol precipitation impurity removal and AB-8 macroporous resin gradient elution. Experiments show that the extract can significantly reduce fasting blood glucose of type 2 diabetes mice induced by high-fat and high-sugar diet combined with STZ, improve sugar tolerance and insulin resistance, and synchronously regulate the blood fat level, and shows an excellent glucose and lipid metabolism synergistic improvement effect. The extract disclosed by the invention provides a choice for developing a safe and effective glycolipid metabolism regulator.

The invention relates to the technical field of medical artificial intelligence, and particularly discloses a method for establishing a disease prediction model of GCK-MODY in gestational diabetes population based on machine learning. The model takes five clinical characteristics as input variables: a body mass index before pregnancy, fasting blood glucose and glycosylated hemoglobin levels during GDM diagnosis, continuous multi-generation diabetes family history and a newly discovered predictive factor, namely GDM diagnosis week of pregnancy. A classification model is constructed through a support vector machine algorithm, and a SHapley additive interpretation method is adopted to provide global and local interpretation of a prediction result, so that model transparency is enhanced. The area of the model under a curve in a test is obviously superior to that of an existing screening standard. The invention also provides an electronic device, a storage medium and a prediction system comprising the model, which can assist clinicians in early recognition of GCK-MODY high-risk patients, provide decision support for targeted gene detection, avoid unnecessary enhanced hypoglycemic treatment of pregnant women, reduce the risk of maternal and infant complications, and promote precise medical development of gestational diabetes mellitus.

The invention discloses application of indoleacetic acid in diagnosis and treatment of gestational diabetes mellitus. Clinical queue research finds that the concentration of serum indoleacetic acid of pregnant women in a gestational diabetes mellitus group is remarkably lower than that of pregnant women in a healthy control group, and high diagnosis efficiency is achieved. Animal experiments further prove that in a high fat diet induced mouse model with gestational diabetes mellitus, the exogenous indoleacetic acid is supplemented, so that the fasting blood glucose of a female mouse with gestational diabetes mellitus can be reduced, abnormal glucose tolerance and insulin resistance can be improved, and the indoleacetic acid is free of embryotoxicity, safe and reliable. The application provides a new thought and means for early diagnosis and effective treatment of gestational diabetes mellitus, and has a wide application prospect.

The invention relates to the technical field of medicine, in particular to application of PC (17: 0 / 0: 0) in preparation of medicine for improving glucose metabolism disorder, clinical research finds that the level of serum PC (17: 0 / 0: 0) is in significant negative correlation with fasting blood-glucose and is in significant positive correlation with the levels of serum odd-chain fatty acids (C15: 0, C17: 0 and C19: 0). Mechanism research shows that PC (17: 0 / 0: 0) can be directly combined with and activate PPARalpha so as to up-regulate HACL1 expression and promote synthesis of endogenous odd-chain fatty acid, so that insulin sensitivity and glucose homeostasis are improved, and a new strategy is provided for developing PC (17: 0 / 0: 0)-based hypoglycemic drugs or health-care foods for assisting in regulating blood sugar.

The invention discloses a prediction model for enteral nutrition intolerance occurrence risk of an adult patient with severe burn and application thereof, and belongs to the field of disease risk prediction. According to the method, risk factors of enteral nutritional feeding intolerance of the serious burn patient are screened, and the EFI risk prediction model of the adult serious burn patient is established and verified based on a Logistic regression analysis method, so that a scientific basis is provided for early clinical recognition of high-risk patients and implementation of preventive intervention. Risk factors for occurrence of EFI (Extensible Firmware Index) of severe burn patients of adults are explored, the risk factors comprise the number of basic diseases of subjects, whether intestinal probiotics are used or not, the number of white blood cells within 24 hours of hospital admission, fasting blood-glucose within 24 hours of hospital admission and the total area of burn, and a risk prediction model is constructed based on the risk factors. And reference is provided for early clinical recognition of high-risk groups with intolerant enteral nutrition feeding of serious burn patients.

The present application relates to the technical field of biotechnology, and discloses a plant Lactobacillus plantarum XKFY202518 and application of the plant Lactobacillus plantarum XKFY202518 in preparation of a type 2 diabetes auxiliary preparation for improving insulin resistance and regulating blood lipid, the plant Lactobacillus plantarum XKFY202518 has a preservation number of CGMCC No.34745 in China General Microbiological Culture Collection Center, and a preservation date of June 3, 2025.The plant Lactobacillus plantarum XKFY202518 separated by the present application can effectively reduce the fasting blood glucose level, insulin level, total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, alanine aminotransferase level and aspartate aminotransferase level of a diabetic mouse, and increase the high-density lipoprotein cholesterol level of the mouse serum, thereby improving the hyperglycemia and hyperlipidemia symptoms of a type 2 diabetes mouse.

The invention relates to lactobacillus paracasei KXW5 with a hypoglycemic function and application thereof, and belongs to the technical field of microorganisms. In order to excavate a microecological preparation for treating hyperglycemia-related diseases, a strain of lactobacillus paracasei KXW5 is separated, and in-vivo and in-vitro experiments prove that the strain has remarkable blood sugar reducing capacity, including promoting proliferation of high-glucose-induced INS-1 cells, improving the relative expression quantity of MafA genes in the high-glucose-induced INS-1 cells and improving the blood sugar reducing capacity. The fasting blood glucose level, postprandial blood glucose level, insulin resistance level, glycosylated hemoglobin level, liver copper ion level and the expression level of copper death related genes FDX1 and DLAT in the liver of the type II diabetes mellitus patient are reduced, and the oral glucose tolerance of the type II diabetes mellitus patient is enhanced. The strain KXW5 provided by the invention can be used for preparing medicines for reducing blood sugar and preventing and / or treating diabetes mellitus or health-care foods for assisting in reducing blood sugar, and opens up a new way for preventing and treating diabetes mellitus.

Disclosed herein are FABP inhibitor compounds and their use in pharmaceutical compositions for the treatment of diseases, including cancers that highly express any of FABP, particularly triple negative breast cancer (TNBC), and other inflammation-inducing diseases, including cancer that highly express any of FABP. Comprise cardiovascular diseases, obesity or obesity-related diseases, diabetes, dyslipidemia, impaired blood glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune diseases, pain and dementia. Also disclosed herein are methods for preparing the disclosed compounds.

Methods, devices and system for determining fasting glucose level information and post-prandial glucose level information for diagnosing pre-diabetic and diabetic conditions based on monitored glucose measurements are provided.

The invention relates to the technical field of pregnant woman delivery time prediction, in particular to a pregnant woman delivery time prediction system based on big data analysis, and the system carries out the weighted fusion of the ratio of the abdominal circumference of a fetus to the femur length, a fetus weight estimation value and a fetus weight increase rate to obtain a fetus metabolic load index; calculating to obtain an insulin resistance index change rate according to the fasting insulin level and the fasting blood glucose level; calculating the blood glucose fluctuation amplitude of the continuous blood glucose monitoring data of the maternal body, and calculating the area abnormal increment under the blood glucose curve; analyzing the blood glucose fluctuation amplitude, the insulin resistance index change rate and the abnormal increment of the area under the blood glucose curve to obtain a maternal metabolic stress index; and when a dynamic imbalance critical value obtained by carrying out load-stress imbalance analysis on the fetal metabolic load index and the maternal metabolic stress index exceeds a preset dynamic imbalance critical threshold value, generating predicted delivery time and outputting early warning information. And the accuracy of predicting the delivery time of the pregnant woman with the gestational diabetes mellitus is effectively improved.

The invention discloses application of ketoisophorone and benzyl benzoate in preparation of a medicine for treating diabetes, and belongs to the technical field of biological medicine. In-vivo and in-vitro studies find that after a T2DM animal model and a GlcN cell model are treated through KSP independent administration, BZT independent administration and KSP and BZT 1: 3 combined administration, compared with a model group, the blood glucose regulation effect of a combined administration group is most remarkable: the area under an fasting blood glucose and oral glucose tolerance test (OGTT) curve is in dose-dependent reduction, and the area under the curve is in dose-dependent reduction; an insulin tolerance test (ITT) result shows that the insulin sensitivity is obviously improved; in animal experiments, glycogen generation in liver tissues is increased, and balloon-like deformation and fatty degeneration accumulation conditions are relieved.